IOVAIovance Biotherapeutics, Inc.

$2B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$482,000

Gross Profit

-$4M-805.6% margin

Operating Income

-$121M-25156.8% margin

Net Income

-$116M-24145.0% margin

EPS (Diluted)

$-0.45

QoQ Revenue Growth

+2.8%

Cash Flow

Operating Cash Flow

-$84M

Free Cash Flow

-$87M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$780M

Total Liabilities

$196M

Stockholders' Equity

$585M

Cash & Equivalents

$115M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$482,000	$0	—
Gross Profit	-$4M	$0	—
Operating Income	-$121M	-$107M	-13.3%
Net Income	-$116M	-$105M	-10.5%

Geographic Segments

Non-US

$500,000100%

IOVA Q4 2023 Earnings — Iovance Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena